Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arjan Hura

Ophthalmology Los Angeles, CA Medical Doctor

NPI 1023549169 CMS profile 5703385

10921 Wilshire Blvd Ste 900, Los Angeles, CA 90024

Open in the dashboard

General payments

$306,210

445 records reported · program years 2019–2025

Research payments

$9

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arjan Hura of Los Angeles, CA is reported in the CMS Open Payments database as having received $306,210 across 445 general payments and $9 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111,847 103
2024 General $102,264 119
2023 General $37,857 103
2022 General $45,516 77
2021 General $4,661 19
2021 Research $9 1
2020 General $3,102 8
2019 General $963 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arjan Hura
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Arjan Hura were reported at $111,847. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Arjan Hura Ophthalmology median Middle half National median
2019 $963 $258 $104–$655 $163
2020 $3,102 $126 $45–$321 $114
2021 $4,661 $205 $76–$534 $132
2022 $45,516 $266 $100–$678 $149
2023 $37,857 $308 $117–$745 $160
2024 $102,264 $340 $127–$846 $164
2025 $111,847 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $212,025 257 payments
  2. Alcon Research LLC $30,050 14 payments
  3. Carl Zeiss Meditec, Inc. $13,763 21 payments
  4. Tarsus Pharmaceuticals, Inc. $12,583 13 payments
  5. Lensar, Inc. $11,938 9 payments
  6. Carl Zeiss Meditec USA, Inc. $6,545 32 payments
  7. Glaukos Corporation $5,380 25 payments
  8. Johnson & Johnson Surgical Vision, Inc. $3,630 11 payments
  9. Rayner Intraocular Lenses Limited $2,784 6 payments
  10. AbbVie, Inc. $2,019 5 payments
  11. Other $5,494 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $198,985 85 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,675 15 payments
  3. Travel and Lodging $33,990 72 payments
  4. Food and Beverage $24,329 266 payments
  5. Honoraria $1,532 2 payments
  6. Education $599 3 payments
  7. Long term medical supply or device loan $63 1 payment
  8. Gift $36 1 payment
Products named General payments · program years 2019–2025
  1. AcrySof IQ PanOptix UV IOL $72,604 41 payments
  2. Clareon $43,863 50 payments
  3. HYDRUS Microstent $39,570 39 payments
  4. NGENUITY $20,753 32 payments
  5. Centurion $18,925 16 payments
  6. Luxor $16,165 19 payments
  7. LENSAR LASER SYSTEM $11,938 9 payments
  8. Clareon PanOptix Pro $11,887 11 payments
  9. ARGOS $11,292 10 payments
  10. AcrySof IQ VIVITY $10,638 8 payments
  11. Other $90,979 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. RxSight Inc $9 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

39

Median for Ophthalmology: 891

Drug cost

$431

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketorolac Tromethamine Generic 39 $431

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$93,810

Medicare's payments for the services billed

Medicare patients

182

Average age 75

Services billed

525

110 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 49%
Ischemic heart disease 27%
Diabetes 21%
Osteoporosis 19%
Depression 17%
Cancer 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $6,460
$6,460 — —
Omidria
  • Rayner Intraocular Lenses Limited $81
$81 — —
OXERVATE
  • Dompe US, Inc. $17
$17 — —
MIEBO
  • Bausch & Lomb Americas Inc. $16
$16 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record